Enveric Biosciences is a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of cancer treatments. Enveric Biosciences has set out with the goal of rigorously testing natural compounds, starting with cannabinoids, to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs.
Stock Performance
Enveric Biosciences News 24 articles
- Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development
- Enveric's lead candidate EB-003 shows positive preclinical signal in a PTSD fear model
- Enveric Biosciences CEO Issues Letter to Shareholders
- Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office
- Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”
- Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to be Dosed Orally
- Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
- Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
- Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
- Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
- Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
- Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
- Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Drug Candidates
- Diamond Equity Research Initiates Coverage on Enveric Biosciences Inc. (NASDAQ: ENVB)
- Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results
- Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)
- Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
- Joseph Tucker, CEO of Enveric Biosciences, Sits in the Investor Hotseat on December 8th
- Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference
- Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines
- Enveric Biosciences Announces Reverse Stock Split
- Enveric Biosciences Announces Closing of MagicMed Industries Acquisition
- MagicMed: Finding the Derivative with Dr. Joseph Tucker
- Enveric Biosciences Announces Agreement to Acquire MagicMed Industries